|
|
|
|
|
| October 20, 2011 | ISSUE NUMBER 222 VOL 8 |
|
R&D
A Fresh Take on R&D Costs: It's Industry's Problem
If there is one message that Big Pharma has applied consistently over the years, it is that drug development is very expensive. But, like everything else, that consensus is now being "goosed"—and from within the industry's own ranks at that
...Read More
Global
Think Not What India and China Can Do for You …
Executives faced with mouth-watering growth rates in the Chinese and Indian pharmaceutical markets—as opposed to broad plateaus in the US and Europe—should first think about what they have to offer, instead of what they can grab, according to panelists at the Center for Healthcare Innovation's inaugural symposium ...Read More
Regulatory
Compliance Issues Top Driver of Change
Last year, only 2 percent of respondents surveyed by Cegedim cited regulatory and compliance issues as a driver of new technology adoption. But a repeat of the survey, released last week, found that number had jumped to 16 percent
...Read More
Advertisement
Leadership and Strategy in Pharmaceuticals and Biotech
 http://www.exed.hbs.edu/programs/lspb/Pages/default.aspx
Revolutions in technology, markets, and government policy are transforming the playing field for pharmaceutical and biotechnology companies. This program prepares high-potential executives to become better managers and leaders by presenting new ways to manage risk, foster innovation, and capitalize on emerging opportunities. |
Economy
Tax Breaks for Big Pharma: A Remedy for Unemployment?
Worried about America's persistently high rate of unemployment (and his bid for re-election), President Obama is urging Congress to pass portions of his jobs bill. In addition to aiding the economy, creating jobs could help reduce the number of people who are forgoing medications, which would be a boon for the pharmaceutical industry ...Read more
Vaccines
Are We a Step Nearer to an HIV Vaccine?
Researchers at the Massachusetts Institute of Technology recently reported on an important advance in the development of an HIV vaccine, writes Patricia Van Arnum ...Read more
|
|
|
 // Roche (Nutley, N.J.) announced the appointment of Hyam Levitsky, MD, as Head of Cancer Immunology Experimental Medicine. // Nycomed (Zurich, Switzerland), a Takeda Company, announced the appointment of Jostein Davidsen as Head of Emerging Markets, in addition to his current role as Area Head of Russia/CIS. // Dr. Alessandro Baldi joined Protea Biosciences (Morgantown, W.Va) as Vice President and General Manager. //
Aptuit (Greenwich, Conn.) appointed Dr. Jan-Olav Henck as Chief Scientific Officer.
//
Among the pharmaceutical industry winners named at the 8th Annual International Business Awards ceremony in Abu Dhabi on Oct. 8 were Franz B. Humer, Chairman of Roche (Executive of the Year) and PAREXEL International (Company of the Year). GlaxoSmithKline (Istanbul, Turkey) was presented with the Apps and Interactive Multimedia Awards (Sales) for its proDG Sales Kit App. |
|
|
|
|
|
|
|
 |
|
 |
| |
 |
| |
 |
|
 |
Do you think FDA and USP should work more closely together on monographs and general chapters?
a) Yes
b) No
|
|
|
|
|
You
are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To
ensure delivery to your Inbox, please add us to your
address book. If you need help doing this, click
here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
